PolyPeptide Group AG announced that shareholders approved all proposals put forward by the Board of Directors at the Company's fifth annual General Meeting with a large majority. The Chair of the Board of Directors, Peter Wilden, welcomed shareholders at the meeting held at the Chollerhalle in Zug, where 26,780,855 shares with voting rights were represented, corresponding to 80.85% of the issued registered shares.
All six members of the Board of Directors proposed for re-election were appointed for a term ending at the conclusion of the next annual General Meeting in 2027. Peter Wilden was re-elected as Chair, and both Philippe Weber and Peter Wilden were individually re-elected as members of the Remuneration and Nomination Committee for the same term. This continuity in leadership provides stability for PolyPeptide, a specialized Contract Development & Manufacturing Organization for peptide-based active pharmaceutical ingredients serving the fast-growing pharmaceutical and biotech markets.
Additional approved proposals included the re-election of the Statutory Auditors and Independent Proxy, approval of maximum aggregate compensation amounts for the Board of Directors and Executive Committee, and granting discharge to all members of both bodies for their activities during the 2025 financial year. Shareholders also approved the Management Report, Statutory Financial Statements, Consolidated Financial Statements, and report on non-financial matters for 2025, along with the Remuneration Report 2025 in a separate consultative vote.
The minutes of the AGM 2026 will be available within 15 days on the Company's website at https://polypeptide.com. The next annual General Meeting is scheduled for April 7, 2027. For business leaders tracking the peptide therapeutics sector, this shareholder endorsement reflects confidence in PolyPeptide's governance as it capitalizes on growing demand for peptide-based drugs, particularly in metabolic diseases including GLP-1 therapies where the company has significant exposure.
PolyPeptide operates a global network of six GMP-certified facilities in Europe, the U.S., and India, supporting customers from pre-clinical to commercial stages. The strong shareholder support for management's proposals suggests alignment on strategic direction as the company contributes to health solutions for millions of patients worldwide. This governance stability is particularly relevant for technology and business leaders evaluating investment opportunities in specialized pharmaceutical manufacturing, where regulatory compliance and operational excellence are critical competitive advantages.
